Results 71 to 80 of about 1,349 (113)

X-linked Agammaglobulinemia First Diagnosed in Adulthood with Recurrent Pneumonia and Multiple Warty Skin Nodules. [PDF]

Intern Med
Isawa M, Tokunaga Y, Tominaga M, Yamada H, Sudou M, Sumita S, Tokisawa S, Okumiya K, Houjou K, Gotoh K, Nishikomori R, Kawayama T, Hoshino T, Manabe T.   +13 more
europepmc   +1 more source

Zanubrutinib-based regimen as the salvage or bridging treatment of CART therapy in relapsed or refractory, non-germinal center B-cell-like diffuse large B-cell lymphoma: a retrospective multicenter cohort study. [PDF]

Front Immunol
Lu Y, Ye S, Zhou L, Yuan X, Li P, Qian W, Liang A.   +6 more
europepmc   +1 more source

Bruton's Tyrosine Kinase Inhibitors in Multiple Sclerosis. [PDF]

Drugs
Lambe J, Fox RJ.
europepmc   +1 more source

Case Report: Preserved umbilical cords underscore family histories of inborn errors of immunity. [PDF]

Front Immunol
Nishimura M, Tomomasa D, Suzuki R, Miyaoka F, Kanegane H.   +4 more
europepmc   +1 more source

Exploratory Covalent Docking of Michael-Acceptor Natural Products at Reactive Cysteines in Cancer Tyrosine Kinases. [PDF]

Int J Mol Sci
Lobo F, Pérez de la Lastra JM, Curieses CM, Bustamante-Munguira E, Juan CA, Pérez-Lebeña E.   +5 more
europepmc   +1 more source

Real-world treatment patterns of Bruton tyrosine kinase inhibitors in mantle cell lymphoma in a community oncology setting. [PDF]

Future Oncol
Shah BD, Xue M, Furnback W, Yang K.
europepmc   +1 more source

BTK inhibitors potently impair platelet aggregation as a class effect independent of BTK specificity or dose in CLL and MCL. [PDF]

J Clin Exp Hematop
Kojima K, Watanabe S, Takeuchi A, Kunisawa N, Yoshida S.   +4 more
europepmc   +1 more source

A pharmacovigilance study of Bruton's tyrosine kinase inhibitors: a multidimensional analysis based on FAERS and VigiBase. [PDF]

Front Immunol
Qu H, Jia Y, Liu Z, Li Z, Zhao X, Wu Z, Fan G, Lou Y.   +7 more
europepmc   +1 more source

Bruton's Tyrosine Kinase Inhibitors in Multiple Sclerosis: Mechanistic Considerations Across Relapsing and Progressive Disease. [PDF]

Molecules
Ye Q, Ma S.
europepmc   +1 more source

Leveraging Kinase Drugs for Neurosciences: Discovery of Selective, CNS-Penetrant Reversible Bruton's Tyrosine Kinase Inhibitors as Therapeutics for Neuroinflammation. [PDF]

J Med Chem
Hopkins BT, Marx IE, Vandeveer HG, Nevalainen M, Basile R, Bajrami B, Choi CK, Grater RJ, Gu C, Hoemberger M, Kadakia E, Kapadnis SK, Liu Y, Ma B, Magee T, Metrick CM, Mingueneau M, Muste CA, Parker Harp CR, Prince RJ, Santoro JC, Schulz J, Sciabola S, Tang H, Wang T, Meissner R, Bohnert T.   +26 more
europepmc   +1 more source